慢性リンパ性白血病(CLL)治療薬の世界市場2016-2020

◆英語タイトル:Global Chronic Lymphocytic Leukemia market 2016-2020
◆商品コード:IRTNTR9378
◆発行会社(調査会社):Technavio
◆発行日:2016年6月1日
◆ページ数:78
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、慢性リンパ性白血病(CLL)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、慢性リンパ性白血病(CLL)治療薬の世界市場規模及び予測、種類別分析、市場シェア、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market
Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
• Acute myeloid (or myelogenous) leukemia (AML)
• Chronic myeloid (or myelogenous) leukemia (CML)
• Acute lymphocytic (or lymphoblastic) leukemia (ALL)
• CLL

Technavio’s analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F. Hoffman-La Roche
• AbbVie
• Teva Pharmaceuticals
• Gilead Sciences
• Novartis
• Johnson & Johnson

[Other prominent vendors]
• Altor BioScience
• Amgen
• Arno Therapeutics
• AstraZeneca
• Bellicum Pharmaceuticals
• Biogen
• BioLineRx
• Boston Biomedical
• Celgene
• Emergent BioSolutions
• Genzyme
• iDD biotech
• Immunomedics
• Infinity Pharmaceuticals
• Innate Pharma
• Karyopharm Therapeutics
• Ligand Pharmaceuticals
• MedImmune
• Merck Sharp & Dohme
• Molecular Templates Inc.
• MorphoSys
• Ono Pharmaceutical
• Portola Pharmaceuticals
• Regeneron Pharmaceuticals
• Sunesis Pharmaceuticals
• TG Therapeutics
• TheraMAB
• XEME Biopharma
• Xencor
• ZIOPHARM Oncology

[Market driver]
• Special regulatory designations
• For a full, detailed list, view our report

[Market challenge]
• High cost of therapy
• For a full, detailed list, view our report

[Market trend]
• Rise in development of combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Types of CLL
• Symptoms
• Diagnosis
• Staging
• Management
• Key buying criteria

PART 06: Pipeline analysis
• Acalabrutinib
• TG-1101 + ibrutinib
• TGR-1202
• Venetoclax + obinutuzumab
• Venetoclax + rituximab
• REVLIMID
• Duvelisib

PART 07: Market landscape
• Global CLL therapeutics market
• Total addressable market for global CLL therapeutics
• Five forces analysis

PART 08: Market segmentation by ROA
• Oral
• Parenteral

PART 09: Market segmentation by type of molecule
• Small molecules
• Biologics

PART 10: Geographical segmentation
• Global CLL therapeutics market by geographical segmentation 2015-2020
• CLL therapeutics market in Americas
• CLL therapeutics market in EMEA
• CLL therapeutics market in APAC

PART 11: Market drivers
• Special regulatory designations
• Recent drug approvals
• Application for expanded indication approvals
• Increase in patient pool

PART 12: Impact of drivers

PART 13: Market challenges
• High cost of therapy
• Availability of chemotherapy and off-label drugs
• Adverse effects of drugs
• Stringent regulatory guidelines

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Joint ventures and partnerships
• Patient assistance programs
• Rise in development of combination therapies
• Growing public awareness

PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• AbbVie
• Teva Pharmaceuticals
• Johnson & Johnson
• Gilead Sciences
• Novartis
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Timeline of development of leukemia drugs
Exhibit 03: Snapshot of CLL
Exhibit 04: Types of CLL
Exhibit 05: Main diagnostic procedures to determine presence of CLL
Exhibit 06: Other diagnostic procedures to determine presence of CLL
Exhibit 07: Rai stages of CLL
Exhibit 08: Binet stages of CLL
Exhibit 09: Management of CLL
Exhibit 10: Key buying criteria for CLL drugs
Exhibit 11: Pipeline portfolio: Global CLL therapeutics market
Exhibit 12: Percentage share of drug candidates by stage of development 2015
Exhibit 13: Global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 14: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 15: Five forces analysis
Exhibit 16: Segmentation of global CLL therapeutics market by ROA 2015
Exhibit 17: Segmentation of global CLL therapeutics market by type of molecule 2015
Exhibit 18: Segmentation of global CLL therapeutics market based on geography 2015
Exhibit 19: Segmentation of global CLL therapeutics market based on geography 2020
Exhibit 20: Global CLL therapeutics market by geography 2015-2020 ($ millions)
Exhibit 21: Global CLL therapeutics market by geography 2015-2020
Exhibit 22: CLL therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 23: CLL therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 24: CLL therapeutics market in APAC 2015-2020 ($ millions)
Exhibit 25: Global CLL therapeutics market: YoY growth and revenue based on geography 2015-2020
Exhibit 26: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 27: Impact of drivers
Exhibit 28: Cost of therapy for CLL
Exhibit 29: Impact of drivers and challenges
Exhibit 30: SWOT: MabThera
Exhibit 31: SWOT: Imbruvica
Exhibit 32: SWOT: Treanda
Exhibit 33: SWOT of Zydelig
Exhibit 34: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indication) 2013-2015 ($ billions)
Exhibit 35: MabThera/Rituxan geographic segmentation by revenue 2015
Exhibit 36: F. Hoffmann-La Roche: Key takeaways
Exhibit 37: AbbVie: Key takeaways
Exhibit 38: Teva Pharmaceuticals: YoY revenue and growth rate of Treanda 2013-2015 ($ millions)
Exhibit 39: Teva Pharmaceuticals: Key takeaways
Exhibit 40: Johnson & Johnson: YoY revenue comparison of Imbruvica (Global) 2013-2015 ($ millions)
Exhibit 41: Johnson & Johnson: YoY revenue comparison of Imbruvica (US) 2013-2015 ($ millions)
Exhibit 42: Johnson & Johnson: YoY revenue comparison of Imbruvica (ROW) 2013-2015 ($ millions)
Exhibit 43: Johnson & Johnson: Geographic segmentation of Imbruvica 2015
Exhibit 44: Johnson & Johnson: Key takeaways
Exhibit 45: Gilead Sciences: YoY revenue and growth rate of Zydelig 2013-2015 ($ millions)
Exhibit 46: Gilead Sciences: Key takeaways
Exhibit 47: Novartis: Key takeaways



【掲載企業】

F. Hoffman-La Roche, AbbVie, Teva Pharmaceuticals, Gilead Sciences, Johnson & Johnson, Novartis, Altor BioScience, Amgen, Arno Therapeutics, AstraZeneca, Bellicum Pharmaceuticals, Biogen, BioLineRx, Boston Biomedical, Celgene, Emergent BioSolutions, Genzyme, iDD biotech, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Karyopharm Therapeutics, Ligand Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Molecular Templates Inc., MorphoSys, Ono Pharmaceutical, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, XEME Biopharma, Xencor, ZIOPHARM Oncology.

【レポートのキーワード】

慢性リンパ性白血病(CLL)、慢性リンパ性白血病(CLL)治療薬、急性骨髄性白血病、慢性骨髄性白血病、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[慢性リンパ性白血病(CLL)治療薬の世界市場2016-2020]販売に関する免責事項
★調査レポート[慢性リンパ性白血病(CLL)治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆